All Eyes Alert - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

All Eyes Alert
It's better to catch costly mistakes in the laboratory before they reach the accounting department.


Pharmaceutical Technology
Volume 36, Issue 5, pp. 16

Under watchful eyes




"It's a good thing we have some observant employees," our GMP Agent-In-Place said sighing. "An employee noticed protein particles when he was bleeding the sterile filter during setup. After a thorough review, the root cause was determined to be an inadequate manual-cleaning process. The filter housing had several valves that need specific cleaning techniques which were not performed. As a result, we rejected three batches worth $1 million in total."


We never learn

"We have four manufacturing sites that make similar biological products around the world," began our GMP Agent-In-Place. "In 1988, there was a leak that allowed the coolant from the jacket into the final stage of one product. We tested hundreds of batches, and ended recalling all in-date products—nearly 300 batches. As one would expect, we put into place many corrective actions (i.e., pressure testing, inspections) in order to prevent recurrence. Fast forward to 2006 and a different site, same company. Another leak in the jacket allowed coolant into the product. Four batches were rejected, and another marathon testing session was undertaken to verify that on market batches were fine.

"Pretty upsetting, yes?" noted our Agent. "But we're not through. This year, the second manufacturing site had another leak affecting a different product. This time, 140 batches were recalled. Not only can't we learn from other manufacturing sites, we can't learn from our own."

It begins with design

"Class A/B filling suites are carefully designed and built to maintain a maximum amount of sterile product protection," explained our GMP Agent-In-Place. "The equipment that controls the temperature, humidity, air pressure, and air filtration are all meticulously sized for this purpose. The rooms are then sealed to prevent incursion of particulates, microbes, or other contaminants. During routine production, we had a drip from the ceiling of the Class B portion of the filling suite during a fill. It turned out the designers had designed for 95% of the local weather conditions. But we manufacture 100% of the days, and it was one of those extreme days that caused the problem. The weather was 98% humidity. The plenum where the air ducts are routed was at ambient temperature and humidity. The air ducts carried chilled air to supply the filling room. The condensation on the outside of the air ducts puddled, and found a crack to drip into the fill room. In the end, insulating the air duct was sufficient to prevent recurrence. The product correction was easy: reject all filled vials."

Check your trends

"Although handling excursions in environmental monitoring is important," our GMP Agent-In-Place pointed out. "One critical use is to trend the data to catch problems before they erupt in significance. During one trend review, we noted that the bulk sterile product-manufacturing department had increased microbe levels and excursions. We asked whether they had changed their SOP or the way that they cleaned, and were told 'No.' When we checked their orders from central stores, we found that they had used 400 mop heads. Reviewing their SOPs and schedules, they actually should have used 1600 single use mop heads. So we asked again what was going on, and were told once again that the SOPs were being followed. Being the helpful guys that we are, we put Quality on the floor for all three shifts during seven days over a month. The trends reversed, the excursions went down, and better yet, the product bioburden was reduced. In addition, their mop head usage increased dramatically."

Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the files of Control, a senior compliance officer. If you have a story to share, please email it to Control at
We won't use any names, but if we do use your experience in the column, you'll receive a Pharmaceutical Technology t-shirt.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here